Search alternatives:
substantial decrease » substantial increase (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
small decrease » small increased (Expand Search)
Showing 1 - 20 results of 6,432 for search '(( significant clinical decrease ) OR ( significant ((substantial decrease) OR (small decrease)) ))', query time: 0.41s Refine Results
  1. 1
    The spike-in of synthetic hsa-lest-7a-5p miRNA decreases the Ct Values of extracted small RNA samples.

    The spike-in of synthetic hsa-lest-7a-5p miRNA decreases the Ct Values of extracted small RNA samples. by Marc Van Der Hofstadt (1423027)

    Published 2024
    Save to List
    Saved in:
  2. 2
    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial

    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... by Chanel Avenant (409756)

    Published 2025
    “…The substantial and differential decrease in testosterone and SHBG levels does not explain our previous finding of no detected decrease in risky sexual behavior or sexual function for DMPA-IM or NET-EN users from D0 to 25W. …”
    Save to List
    Saved in:
  3. 3
    Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.

    Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration. by Denis Mustafov (19137870)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC.

    Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    General characteristics and clinical data of the subjects included in the study.

    General characteristics and clinical data of the subjects included in the study. by Spela Kokelj (8356644)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations.

    Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

    Published 2025
    Save to List
    Saved in:
  7. 7
    Loss of <i>Rab23</i> decreases ciliation in MEFs and Tbr1 + intermediate progenitors.

    Loss of <i>Rab23</i> decreases ciliation in MEFs and Tbr1 + intermediate progenitors. by Wan Ying Leong (22075947)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Estimated detected and non-detected colorectal cancer rates and their clinical stages based on colorectal cancer screening in Minamisoma City in 2011.

    Estimated detected and non-detected colorectal cancer rates and their clinical stages based on colorectal cancer screening in Minamisoma City in 2011. by Hiroaki Saito (24514)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Degeneration Saline group presented with significant decreased final weight in relation to other groups.

    Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

    Published 2025
    Save to List
    Saved in:
  11. 11
    Centrifuged FMT products consistently exhibit the lowest median log<sub>10</sub> drop of CFU/g following freezing and lyophilization. In contrast, unprocessed feces exhibited the greatest median log<sub>10</sub> drop and had a statistically significant loss of bacterial viability across both storage conditions. Products with M:D were the only cryopreserved products to exhibit a significant decrease in surrogate bacterial viability after freezing. However, M:D FMT products exhibited the smallest median loss of bacterial viability following lyophilization and outperforms other lyopreservatives. Data is represented as median and range in parentheses. Significant p-values are bolded. Abbreviations: C, centrifuged; NC, not centrifuged; MD, maltodextrin and trehalose.

    Centrifuged FMT products consistently exhibit the lowest median log<sub>10</sub> drop of CFU/g following freezing and lyophilization. In contrast, unprocessed feces exhibited the g... by Nina K. Randolph (21030732)

    Published 2025
    Save to List
    Saved in:
  12. 12
    Introgression decreases allelic shuffling.

    Introgression decreases allelic shuffling. by Enrique J. Schwarzkopf (6579275)

    Published 2025
    Save to List
    Saved in:
  13. 13
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  14. 14
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  15. 15
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  16. 16
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  17. 17
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  18. 18
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  19. 19
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  20. 20
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:

Search Tools: